Abstract
Cannabinoids, the active components of the hemp plant Cannabis sativa, along with their endogenous counterparts and synthetic derivatives, have elicited anti-cancer effects in many different in vitro and in vivo models of cancer. While the various cannabinoids have been examined in a variety of cancer models, recent studies have focused on the role of cannabinoid receptor agonists (both CB(1) and CB(2)) in the treatment of estrogen receptor-negative breast cancer. This review will summarize the anti-cancer properties of the cannabinoids, discuss their potential mechanisms of action, as well as explore controversies surrounding the results.
MeSH terms
-
Animals
-
Antineoplastic Agents, Phytogenic / pharmacology*
-
Antineoplastic Agents, Phytogenic / therapeutic use
-
Benzoxazines / pharmacology
-
Breast Neoplasms / drug therapy
-
Breast Neoplasms / metabolism
-
Cannabinoids / pharmacology*
-
Cannabinoids / therapeutic use
-
Cell Proliferation / drug effects
-
Cell Survival / drug effects
-
Female
-
Humans
-
Male
-
Morpholines / pharmacology
-
Naphthalenes / pharmacology
-
Neoplasms / drug therapy*
-
Neoplasms / metabolism
-
Neoplasms / pathology
-
Receptor, Cannabinoid, CB1 / agonists
-
Receptor, Cannabinoid, CB1 / metabolism
-
Receptor, Cannabinoid, CB2 / agonists
-
Receptor, Cannabinoid, CB2 / metabolism
-
Receptors, Estrogen / analysis
-
Signal Transduction / drug effects
Substances
-
Antineoplastic Agents, Phytogenic
-
Benzoxazines
-
Cannabinoids
-
Morpholines
-
Naphthalenes
-
Receptor, Cannabinoid, CB1
-
Receptor, Cannabinoid, CB2
-
Receptors, Estrogen
-
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone
-
1,1-dimethylbutyl-1-deoxy-Delta(9)-THC